1a). Darzalex (daratumumab), an anti-CD38 monoclonal antibody (mAb) for multiple myeloma, continues to be the biggest single growth driver for the company. AbbVie held on to the number two spot ...

A recent groundbreaking study published in Nature has opened a promising new chapter in the treatment of traumatic brain ...

Programme will launch the implementation of the “Mangrove Restoration: Nature-Based Solutions in Biosphere Reserves of Latin America and the Caribbean” project (MangRes Project), thanks to the ...

Let’s get this out of the way—any scientist studying Uranus will tell you that they’re tired of the planet being the butt of ...

Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, today announces the appointment of clinical nephrology experts An De Vriese, ...

In their new study, the researchers showed that mAb 3A6 helps block infection by binding to an important ... Ph.D., MBA, who led the recent Nature Communications study alongside John A. G. Briggs, ...

Hastie et al, Anti-Ebola virus mAb 3A6 protects highly viremic animals from fatal outcome via binding GP(1,2) in a position elevated from the virion membrane, Nature Communications (2025).

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

ADCs are currently at the forefront of cancer treatment, but persistent drug development challenges call for a new approach.